LDLR and atherosclerosis: Recent studies using LDL receptor-deficient mice (Ldlr−/− mice) as a model of atherosclerosis showed that the selective removal of active foam cells expressing senescence-associated β-galactosidase (SA-β-Gal) using the Bcl-2 family protein inhibitor ABT-263 perturbs the proatherogenic environament11.